Publication details

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

Authors	DESAI Sanjal H SPINNER Michael A EVENS Andrew M SYKOROVA Alice BACHANOVA Veronika GOYAL Gaurav KAHL Brad DORRITIE Kathleen AZZI Jacues KENKRE Vaishalee P CHANG Cheryl MICHALKA Jozef ANSELL Stephen M FUSCO Brendon SUMRANSUB Nuttavut HATIC Haris SABA Raya IBRAHAM Uroosa HARRIS Elyse I SHAH Harsh WAGNER-JOHNSTON Nina ARAI Sally NOWAKOWSKI Grzegorz S MOCIKOVA Heidi JAGADEESH Deepa BLUM Kristie A DIEFENBACH Catherine IYENGAR Siddharth RAPPAZZO K C BAIDOUN Firas CHOI Yun PROCHAZKA Vit ADVANI Ranjana H MICALLEF Ivana
Year of publication	2023
Type	Article in Periodical
Magazine / Source	Blood advances
MU Faculty or unit	Faculty of Medicine
Citation
web	https://ashpublications.org/bloodadvances/article/7/23/7295/497969/Overall-survival-of-patients-with-cHL-who-progress
Doi	http://dx.doi.org/10.1182/bloodadvances.2023011205
Keywords	cHL; patients; survival; autologous stem cell transplant
Description	In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.